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Abstract. Biochemical markers of bone resorption can be
used clinically to predict the risk of osteoporosis-related
fractures (prognostic tool) and to assess the response of an
osteoporotic patient to an antiresorptive therapy (monitoring
tool). Our aim was to assess the ability of four currently
marketed biochemical markers of bone resorption, based on
the measurement of degradation products from collage type
I telopeptides to monitor the elevated resorption associated
with menopause. Women (846) were stratified for meno-
pause, age, and bone mineral density and the following
markers were measured: urinary cross-linked N-
telopeptides of type I collagen (NTx), the levels of break-
down products of type I collagen C-telopeptides in serum
(S-CTx), and in urine, by ELISA (U-CTx-E), and RIA (U-
CTx-R). Furthermore, the ratio (a/b) between the aL form
of CTx measured in the CTx RIA and the bL form mea-
sured in the ELISA was calculated. The mean difference
was calculated for each marker in women with osteopenia
(Op) or osteoporosis (PMO) (WHO definition) compared
with healthy premenopausal (Pre) women and postmeno-
pausal (N Post) women with normal bone mass. Serum CTx
showed the highest elevation in post- compared with pre-
menopausal women. All marker values were significantly
higher in Op and PMO subjects compared with both Pre and
to N Post women. Compared with premenopausal values,
the largest elevation in both Op and PMO women was ob-
served for serum CTx. Compared with N Post, urine NTx
showed the highest increase in OP subjects. The a/b CTx
ratio was elevated in post- compared with Pre women, but
there was no difference in the ratio among N Post, Op, or
PMO women. In conclusion, postmenopausal women
showed elevated turnover with all bone resorption markers,
but with substantial individual variation in resorption levels.
Furthermore, the turnover process in postmenopausal
women appears to be quantitatively different from the pre-
menopausal stage, apparent as altered a/b CTx ratios.
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Assessment of bone physiology has been greatly improved
by the development of specific and sensitive markers of
bone remodeling [1, 2]. Biochemical markers have advan-
tages because they are noninvasive, inexpensive, reflect
turnover in the whole skeleton, and allow repeated evalua-
tion [3, 4]. Furthermore, biochemical markers of bone re-
modeling are a valuable supplement to bone mineral density
measurement (BMD), as they provide a dynamic measure of
the current bone turnover state compared with the static
measure of skeletal status provided by BMD. Thus, bio-
chemical markers of bone turnover provide a rapid assess-
ment of the effects of antiresorptive therapies such as hor-
mone replacement therapy, bisphosphonates, and calcitonin
which induce a decrease in the levels of bone markers that
is correlated with the long-term effect of such treatments on
bone mass [5–15]. Due to the small annual changes in
BMD, the effect of antiresorptive therapy can only be reli-
ably monitored by BMD measurement after several years
followup [5, 10, 13].
Bone markers might also be used to prognose a high rate
of bone less in postmenopausal women who would subse-
quently develop osteoporosis and fractures [16–25]. Bone
turnover increases after menopause and remains elevated in
late postmenopausal women. It has been demonstrated that
bone resorption markers are an independent predictor of
fracture risk with the same predictive value as BMD mea-
surements [19, 22].
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bone resorption have been developed. These assays measure
degradation products derived from the N- and C- terminal
telopeptide regions of type I collagen in either urine or
serum samples [1, 5, 25–31]. The application of these mark-
ers in daily practice will depend upon their ability to rank
healthy subjects regarding their turnover status and to dis-
tinguish between individual subjects in terms of their re-
sponse to antiresorptive therapy [1, 4, 32]. For monitoring
use, the intraindividual variation increase seen at meno-
pause and responsiveness to various anti-resorptive thera-
pies is important [5, 27, 33]. For prognosis of future BMD
and fracture risk, marker levels and their changes in the
individual patient must be correlated with levels and
changes in BMD and ultimately with fracture occurrence.
Clinical information may also be derived from biochemi-
cal marker data is an assessment of the average ‘age’ of the
resorbed bone. b-Aspartate isomerization, which occurs as a
slow spontaneous reaction in the C-telopeptide of type I
collagen, has been suggested to provide a measure of the
bone ‘age’ [34, 35]. C-telopeptide fragments measured in
the urine CrossLaps (CTx) radioimmunoassay (RIA) are in
the authentic aL form characteristic of newly synthesized
collagen molecules [34, 36]. The corresponding fragments
measured in the urine CTx ELISA, as well as in the serum
CTx assay, are in the isomerized bL form, and thus these
molecules are ‘older’ than the molecules measured in the
RIA [35]. By calculating a ratio between the measures ob-
tained in the two assays (RIA/ELISA » a/b), the age of the
resorbed bone can be measured. In addition to isomeriza-
tion, the aspartate residue of the CTx epitope is also sus-
ceptible to racemization, and laboratory assays specific for
the racemized forms have been developed [35]. Ratios be-
tween the aL form and the racemized forms also provides a
measure of collagen age, and such ratios are elevated in
Pagets disease and certain forms of bone metastasis [35,
37]. However, whether these ratios have any value for clini-
cal assessment of osteoporosis remains to be demonstrated.
To address these issues, we have measured four cur-
rently marketed biochemical markers of bone turnover in a
cohort of 846 women, stratified for menopause, age, and
BMD. We calculated the mean changes for each parameter
in women with Op or PMO (WHO definition) [38] com-




The patients were recruited from two outpatients facilities (Center
for Clinical and Basic Research, Ballerup, Denmark and Bone and
Cartilage Metabolism Unit, University of Lie`ge, Lie`ge, Belgium)
specializing in diagnosis and treatment of skeletal disorders. The
study population (846 women) were spontaneously measured for
bone mineral density and bone turnover. Women suffering from
disorders or treated with drugs that might interfere with bone den-
sity and/or bone turnover were excluded from the study. The
women were stratified based on their menopausal status (premeno-
pausal versus postmenopausal), and BMD values. BMD values
were classified in accordance with the WHO definition of normal-
ity (N Post)(T-score at the spine and hip >−1), Op (T-score at the
spine between −1 and −2.5), and PMO (T-score at the spine <−2.5)
[38]. Blood samples were taken after overnight fasting. Venous
blood (10–15 ml) was drawn from the fasting women between
9:00 a.m. and 11:00 a.m. The blood sample was centrifuged, di-
vided into two to three aliquots, and stored at − 80°C until assayed.
Second morning spot urine was concomitantly collected and stored
under similar conditions. The height and weight of the subjects
were determined and used to calculate BMI (body mass index).
Menopausal age was noted for the postmenopausal women.
Measurement of Biochemical Markers
Serum breakdown products of type I collagen C-telopeptides
(CTx) were measured with an enzyme-linked immunosorbent as-
say (ELISA) (Serum CrossLaps™ One Step ELISA; Osteometer
BioTech A/S, Herlev, Denmark) using two monoclonal antibodies
directed against a b-isomerized form of an 8 amino acid sequence
(EKAHD-b-GGR) of the C-telopeptide of the a 1 chain of type I
collagen [30]. To obtain a signal in the assay, two sequences must
be cross-linked. The assay has intra- and interassay CVs of 5.2 and
6.7%, respectively, and results are expressed in pM.
Urinary CTx were simultaneously measured both by ELISA
and RIA (CrossLaps™ ELISA and a-CrossLaps™; Osteometer
BioTech A/S, Herlev, Denmark) The assays have intra- and inter-
assay CVs of 5.4 and 7.0%, respectively for the ELISA and 8.6 and
9.8% for the RIA assay. The ELISA uses polyclonal antibodies
directed against the b-isomerized sequence (EKAHD-b-GGR) and
is based on the competitive binding of antibodies to either soluble
peptide or to immobilized synthetic peptide [8, 31]. The RIA uses
a monoclonal antibody (MAb) raised to the 8 amino acid sequence
(EKAHDGGR) and is based on the competitive binding of 125I
labeled Mab to either soluble peptide or to immobilized synthetic
peptide [36]. Urinary cross-linked N-telopeptides of type I colla-
gen (NTx) were measured with an ELISA (Osteomark®; Ostex
International, Inc., Seattle, WA, USA) using a Mab directed
against the N-telopeptide-to-helix intermolecular cross-linking do-
main of the type I collagen isolated from human urine [26]. The
ELISA is based on the competitive binding of the Mab to either
urinary or immobilized antigen. The results were expressed in
nanomoles bone collagen equivalents per liter (nM BCE) and were
corrected by the creatinine concentration (mM) to be expressed in
nM BCE/mmol. The assay has intra- and interassay CVs of 6.0 and
4.0%, respectively.
The urine creatinine level was measured by photometric deter-
mination with the Jaffe method [39] on the multitest analyzer
system Merck MEGA® (Merck, Darmstadt, Germany). Each bio-
chemical measurement was performed in duplicate on fresh
thawed urine or serum aliquot and repeated when the CV for the
double determination was above 15%.
Standardization of Urinary CrossLaps Assays
The mg/liter values obtained in the CrossLaps RIA and ELISA
assays is not corrected to the actual concentration of peptide, but
standardized to a master calibrator used since the CrossLaps
ELISA was first developed. In order to obtain values in the correct
mg/liter units, a correction factor of 3.45*10−2 for the ELISA and
1.93*10−2 for the RIA assay has to be used [40]. For further
conversion to molar concentration, a molecular weight of 869
g/mol for the CrossLaps epitope should be used. The a/b CTx ratio
has to be multiplied by 0.56 to get the ratio in actual molar terms
between the two forms of the collagen type I C-telopeptide in
urine. However, the concentrations obtained directly in the assay
have been used throughout, as this allows direct comparisons with
other published reports on the CrossLaps assays.
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Analysis of Database
The results of the four biochemical markers of bone resorption
were analyzed with the Excel 5.0 software. For each category of
patients and for each biochemical parameter, results are provided
as the mean and standard deviation. A regression analysis was used
to calculate the Pearson’s coefficient for the correlation between
each of the markers of bone resorption in the whole population.
The significance of differences between groups was calculated by
nonparametric Mann-Whitney testing. For the Op and PMO
women, the results (after correction of urinary measurements for
creatinine) are also expressed as the increase in the mean com-
pared with Pre and N Post women. A similar calculation is pro-
vided for N Post versus Pre women. We then calculated the per-
centage of Op or PMO women whose measured values of each of
the bone markers (corrected for urinary creatinine) was higher than
the mean + 2 SD of the value measured, for the same marker, in
Pre or N Post women. Multiple regression analysis was used to
adjust for the influence of age when assessing the significance of
the observed difference in markers between the groups for the two
markers showing a significant correlation to age (s-CTx and u-
NTx).
Results
Table 1 shows the mean value and SD for the four bio-
chemical markers of bone resorption, for Pre and N Post
women. The ratio between CTx measured by RIA (aL) and
ELISA (bL) has also been calculated and included in Table
1. All biochemical markers, as well as the a/b CTx ratio,
were significantly elevated in the postmenopausal group.
The difference between the two groups was most pro-
nounced for the serum CTx marker (s-CTx, 99.8% increase
in postmenopausal women compared with premenopausal).
Average BMI among the pre- and postmenopausal women
was 23.24 ± 2.78 and 25.29 ± 3.54, respectively. This sig-
nificant difference (P 4 0.013) was the result of a signifi-
cant difference in heights (167.63 ± 5.21 versus 162.57 ±
5.48 cm) between the two groups whereas weight was simi-
lar in pre- and postmenopausal women (65.37 ± 8.94 versus
66.76 ± 9.29 kg).
Table 2 shows the Pearson’s coefficient for the correla-
tions between the markers. Correlation between the marker
levels and age of the sampled individuals, as well as the a/b
CTx ratio, is also given in Table 2. The correlations between
the resorption markers are highly significant (P < 0.001):
the highest correlation is observed in the two methods used
to assess urinary CTx, both before and after correcting for
urinary excretion for creatinine (r 4 0.832 and r 4 0.770,
respectively). The markers also show a correlation to the
age of the sampled individuals, ranging from weak correla-
tion for the two urinary CTx assays (P 4 0.05 and P 4
0.016 for the ELISA and RIA assay, respectively) to a stron-
ger correlation for the serum CTx and urinary NTx assays
(P < 0.001). The CTx markers show a relatively low but
significant (P < 0.001) correlation to the a/b CTx ratio. The
u-CTx ELISA measuring the bL form and the serum CTx
assay, which is also specific for the bL forms of the CTx
molecules, show an inverse correlation to the a/b ratio.
The postmenopausal women described in Table 1 were
further divided according to spine BMD measurements into
osteoporotic (PMO, s-BMD < premenopausal mean −2.5
SD), osteopenic (Op, s-BMD between −2.5 and −1 SD be-
low premenopausal mean), and normal postmenopausal (N
Post, with s-BMD above premenopausal mean −1SD)
(Table 3). All marker values are elevated in Op and PMO
subjects compared with both Pre and N Post women (Table
3). The significance of the differences was calculated by
Mann-Whitney testing. Serum CTx and urinary NTx values
were adjusted for the influence of age by multiple regres-
sion analysis. Compared with premenopausal values, the
largest increase in both Op and PMO women is observed for
the mean serum CTx (Fig. 1). Serum CTx measured sig-
nificantly elevated levels in the N Post group compared with
premenopausal women. The levels of the urinary resorption
markers were not significantly elevated in the group of post-
menopausal women with normal BMD compared with pre-
menopausal women (Table 3). The a/b CTx ratio was sig-
nificantly higher in N Post, Op, and PMO women compared
with the premenopausal women, but Op and PMO women
did not have significantly different a/b ratios compared
with N Post women. BMI in the three cohorts was not
significantly different (25.77 ± 2.98, 24.84 ± 2.71, and
25.33 ± 5.35 kg/m2, respectively, for the N Post, Op, and
PMO groups). The menopausal age was also similar in all
Table 1. Biomarker levels in the study cohort stratified according to menopausal status.
Group Age s-CTx u-CTx E u-CTx-R u-NTx a/b CTx
Premenopausal n 29 29 27 25 28 25
Average 38.42 1838.90 198.40 229.21 42.64 1.16
SD 6.01 725.53 89.14 127.38 25.84 0.39
Postmenopausal n 817 800 796 778 798 778
Average 69.79 3753.72 243.83 340.5 58.92 1.52
SD 8.43 2095.69 154.83 340.5 58.92 1.52
Significance of difference <0.0001 <0.0001 0.017 0.0003 0.0041 0.0001
The values listed for the urinary CrossLaps assays are the values obtained in the assays. For conversion to actual concentrations, a
correction factor of 3.45 ⁄ 10−2 for the ELISA and 1.93 ⁄ 10−2 for the RIA assay has to be used [40]. Likewise, the a/b CTx ratio has
to be multiplied with 0.56 to get the actual ratio between the non-isomerized a form and the isomerized b form of the collagen type I
C-telopeptide fragments in urine measured in the CrossLaps assays
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three groups (48.69 ± 6.70, 49.64 ± 6.43, and 49.27 ± 4.36
years, respectively, for the N Post, Op, and PMO groups).
The percentage of Op or PMO women with values
higher than premenopausal mean + 2 SD was calculated for
each of the four markers (Fig. 1B). The mean urinary con-
centration of CTx and NTx was increased 32 and 58%,
respectively, in Op and PMO when compared with N Post,
and the mean serum CTx concentration was 19 and 32%
elevated in these two groups, respectively (Fig. 2). The
percentage of Op and PMO women with values higher than
the mean value + 2 SD observed in normal postmenopausal
women is in the same range for all markers, the values
observed for urinary CTx measured by ELISA being
slightly higher than those observed for the other markers
(Fig. 2B).
Discussion
CTx and NTx are widely considered the most sensitive and
specific of the currently marketed markers of bone resorp-
tion [1, 25, 27]. These markers have been extensively used
for both the assessment of therapeutic efficacy of antire-
sorptive drugs in osteoporosis and for prediction of fracture
risk in postmenopausal women [6–24]. We measured uri-
nary and serum CTx and urinary NTx in a large cohort of
untreated, healthy women stratified on the basis of their
menopausal status and BMD.
Urinary CTx was measured in both ELISA and RIA
formats. These two assays employ different antibodies: the
RIA assay is specific for the authentic aL form of the CTx
epitope, whereas the antibody employed in the ELISA is
specific for the isomerized (‘aged’) bL form [34]. Thus it is
possible to calculate the ratio between the aL and the bL
form of CTx, and this ratio has been suggested to provide an
estimate of the ‘age’ of the resorbed bone [34, 35].
All markers of bone resorption were significantly corre-
lated, with the highest correlation coefficient being ob-
served for urinary CTx, assessed by ELISA and RIA, fol-
lowed by the correlation between urinary NTx and urinary
CTx ELISA. These results are in accordance with previous
studies reporting correlation coefficients slightly lower or in
the same range as those observed in the present investiga-
tion [16, 17, 21, 22, 30]. Interestingly, the a/b CTx ratio
showed relatively poor correlations with the individual bone
resorption markers. This suggests that this ratio provides a
qualitatively different measure of the turnover process. The
higher a/b ratio in the postmenopausal women is likely to
be a reflection of increased turnover rate, and thus a de-
creasing ‘age’ of the resorbed collagen molecules [35, 37].
All four markers were significantly elevated in the post-
menopausal compared with premenopausal women, in
Table 2. Correlation between biochemical markers. Urinary marker values were corrected for creatinine for correlation to serum CTx, age,
and a/b CTx ratio. Values represent Pearson’s correlation coefficients
NTx sCTx uCTx-E uCTx-R a/b CTx
NTx 0.432*** 0.725*** 0.696*** −0.019
SCTx 0.432*** 0.572*** 0.489*** −0.129***
UCTxE 0.725*** 0.572*** 0.832*** −0.247***
UCTxR 0.696*** 0.489*** 0.832*** 0.218***
a/b CTx −0.019 −0.129*** −0.247*** 0.218***
Age 0.124*** 0.169*** 0.068* 0.085* 0.026
*** P < 0.001; * P < 0.05
Table 3. Number of subjects (n), mean value (mean) and standard deviation (SD), and median for each resorption marker in the
postmenopausal women stratified in three groups according to BMD
Group n Age s-CTx u-CTx E u-CTx-R u-NTx a/b CTx
Normal Average 64.5 3046.8 183.0 248.1 42.52 1.57
BMD 104 SD 6.5 1833.2 123.7 213.7 37.3 1.07
(N Post) Difference to Pre P < 0.0001 P < 0.0001* NS NS NS* P < 0.0001
Osteopenia Average 68.9 3742.6 240.6 349.3 56.0 1.56
(Op) 359 SD 8.6 2041.4 151.0 308.3 73.9 1.07
Difference to Pre P < 0.0001 P < 0.0001* P 4 0.032 P 4 0.0003 P 4 0.027* P < 0.0001
Difference to N Post P < 0.0001 P 4 0.012* P 4 0.0001 P 4 0.0002 NS*(p > 0.1) NS (p > 0.1)
Osteoporosis Average 71.22 4007.6 265.7 359.0 67.0 1.47
(PMO) 338 SD 8.8 2184.2 162.3 250.0 47.0 0.7
Difference to Pre P < 0.0001 P < 0.0001* P 4 0.0018 P < 0.0001 P < 0.0001* P < 0.0001
Difference to N Post P < 0.0001 P 4 0.0009* P < 0.0001 P < 0.0001 P 4 0.006* NS (p > 0.1)
* Serum CTx and urinary NTx values were corrected for the influence of age by regression analysis for calculation of the significance
levels of the difference between the groups
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agreement with results reported in previous studies [17, 30,
31, 41–46]. However, the differences between the pre- and
postmenopausal women were relatively low for the three
urinary markers, ranging from a 23 to a 49% increase (for
urine CTx ELISA and urine CTx RIA, respectively).
When the postmenopausal women were divided into
three groups according to BMD status (osteporotic, osteo-
penic, and normal), only the osteoporotic and osteopenic
women had a significant elevation in the levels of urinary
resorption markers compared with the pre- and postmeno-
pausal women with normal BMD. The serum CTx marker
showed a significant elevation of 64% in the N Post group
compared with the premenopausal group and increases of
103.5 and 117.9% in the Op and PMO groups. The lack of
a significant elevation in urinary markers of bone resorption
found in the group of postmenopausal women with normal
BMD may be considered to be in disagreement with many
previous reports [17, 30, 31, 41], but more in accordance
with other studies, which have either failed to show such
differences [25, 43] or reported a relatively large scatter of
the resorption markers around the mean values [42, 44–46].
Most of these studies defined “healthy” postmenopausal
women on the absence of clinical osteoporosis, without as-
sessment of BMD. In the present work, “normal” postmeno-
pausal women (N Post) were selected on the basis of BMD
at the spine and hip levels above premenopausal mean −1
SD (T-score −1). If a high rate of bone turnover is effec-
tively correlated to a fast rate of bone loss, both immediately
after the menopause and later in life [16, 17, 21, 22], it
might thus be logical that N Post women with the highest
BMD have only a relatively placid increase in bone turnover
compared with Prewomen. This hypothesis, however, does
not explain the significantly elevated levels of serum CTx
seen among the N Post women. Serum and urine samples
were obtained at the same time, from the same patients, and
processed under similar conditions. Thus, the samples
should be directly comparable, and technical issues are un-
Fig. 1. (A) Increase (%) in the biochemical markers mean values
among postmenopausal women with normal BMD, osteopenic, or
osteoporotic women compared with values of premenopausal
women. (B) Percentage of the osteopenic and osteoporotic women
with values of each of the biochemical markers higher than the
mean +2 SD for the premenopausal women.
Fig. 2. (A) Increase (%) in the biochemical marker mean values
from osteopenic or osteoporotic women compared with values of
normal postmenopausal women. (B) Percentage of the osteopenic
and osteoporotic women with values of each of the biochemical
markers higher than the mean +2 SD for the normal postmeno-
pausal women.
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likely to affect the discrepancy. Urine samples were cor-
rected for creatinine, excluding a possible role of renal dys-
function, at any rate, very unlikely in women between 55
and 65 years old. We have no definite explanation for the
discrepancy between serum and urinary CTx. However, this
discrepancy may support the suggestion that serum CTx
measurements can be superior to urinary tests, in terms of
specificity and sensitivity, for the detection of hyper remod-
eling stages [5, 27, 29, 33].
The urinary a/b CTx ratio was significantly elevated in
all three cohorts of postmenopausal women compared with
the premenopausal group. However, the a/b CTx ratio was
similar in normal, osteopenic, and osteoporotic postmeno-
pausal women, suggesting that decreased half-life of bone
collagen reflected in the elevated a/b CTx ratio is a com-
mon feature occurring in the menopause, when the turnover
rate is increased [34, 35, 37]. When the a/b CTx ratio was
corrected to reflect the actual molar ratios of the two forms,
the ratio in pre- and postmenopausal women was 0.65 and
0.85, respectively. This is in accordance with previously
published data [40].
Very weak correlations were seen between urinary CTx
and age, whereas the correlation between serum CTx and
age as well as urine NTX and age was significant. It may be
considered surprising that no significant correlation was
found between a/b CTx ratio and age. However, it has been
shown that collagen type I isomerization/racemization have
reached equilibrium in adult individuals [34, 35]. After 20–
30 years the a/b CTx ratio remains relatively constant and
reflects the age of the resorbed collagen rather than the age
of the individual. Menopause induces an increased remod-
eling state reflected as an increase in the a/b CTx ratio, and
the elevated a/b CTx levels occurring at menopause persist
in older women.
Our results showing a consistent increase in urinary and
serum markers of bone resorption in osteopenic and osteo-
porotic women compared with premenopausal or normal
postmenopausal women is in accordance with previous
findings. Women with low BMD and/or fractures of the
spine, forearm, or hip were repeatedly characterized by a
high level of bone resorption, apparent as increased values
of serum and urinary C- and N- terminal telopeptides frag-
ments derived from type 1 collagen [11, 33, 43, 47–50].
Serum CTx shows the highest discrimination between pre-
menopausal women and all groups (normal, osteopenic, and
osteoporotic) of postmenopausal women whereas urinary
NTx was the assay showing the highest differentiation be-
tween postmenopausal women with normal BMD and Op
and PMO women. The value of biochemical markers of
bone resorption as predictors of further occurrence of frac-
tures is based on the hypothesis that women with the highest
rate of bone turnover will experience faster loss of bone and
will develop subsequent fractures. This was confirmed by
prospective studies showing that markers of resorption
could predict the risk of hip fractures independently of
BMD [18, 22]. In this perspective, the optimal marker
would be the one offering the best discrimination between
osteoporotic subjects and age-matched normal subjects. All
the investigated markers appropriately discriminate between
postmenopausal women with normal BMD and osteopenic
or osteoporotic subjects. Urinary NTX shows the most pro-
nounced increase (57.6%) in osteoporotic women compared
with the normal BMD group. When considering the per-
centage of osteopenic or osteoporotic women with values
higher than the mean +2 SD of the normal postmenopausal
women, 11.4 and 12.7% of the women, respectively, had
significant elevation of urinary CTx ELISA levels. The
other markers identified a lower portion of the osteopenic
and osteoporotic women as high turnover individuals by this
stratification method. The a/b CTx ratio was almost iden-
tical in the three cohorts of postmenopausal women sug-
gesting that this parameter reflects a different physiological
process than the individual resorption markers [35, 40].
We conclude that all the four collagen type I-derived
markers of bone resorption are significantly increased in
osteopenic or osteoporotic subjects compared with normal
postmenopausal women. The ratio between authentic and
‘aged’ CTx molecules (a/b ratio) appeared to provide a
quantitatively different measure of the bone turnover pro-
cess. The clinical application of such a ratio will have to be
assessed in future studies.
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